Featured Research

from universities, journals, and other organizations

Angiogenesis Linked To Poor Survival In Patients With Rare Type Of Ovarian Cancer

Date:
February 12, 2009
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
Researchers have found that increased angiogenesis, or blood vessel formation, and vascular endothelial growth factor expression are associated with poor survival in women with sex cord-stromal ovarian tumors.

Researchers from The University of Texas M. D. Anderson Cancer Center have found that increased angiogenesis, or blood vessel formation, and vascular endothelial growth factor expression are associated with poor survival in women with sex cord-stromal ovarian tumors.

Related Articles


This data was presented in a poster session Feb 5 at the Society of Gynecologic Oncologists' 40th Annual Meeting on Women's Cancer.

Sex cord-stromal ovarian tumors are rare, accounting for five to seven percent of all ovarian cancer diagnosed, and there is little data available on how they advance, or metastasize, in patients. These findings provide doctors greater understanding into how they may be able to successfully treat patients with this type of tumor by inhibiting angiogenesis according to the study's authors.

"These tumors tend to metastasize very differently from other, more common types of ovarian tumors," said Jubilee Brown, M.D., assistant professor in the Department of Gynecologic Oncology and lead author on the study. "For instance, sex cord-stromal tumor cells rarely break away and invade the lymph nodes, but we still see evidence of their spread to distant locations in the body such as the abdomen and liver. This unusual progression hinted that a different pattern of metastasis in which tumor cells break off and invade the blood system, may be at play."

The American Cancer Society estimates approximately 21,650 new cases of ovarian cancer were diagnosed in the United States in 2008. There are more than 30 different types of ovarian cancer, categorized by the type of cell where the malignancy begins. Sex cord-stromal ovarian tumors, which develop in the connective tissue that holds the ovary together, are typically diagnosed at an earlier stage.

Researchers looked at 54 sex cord-stromal ovarian tumor samples, 28 from women with primary occurrences and 26 from women with recurrences. The samples were evaluated for two common indicators of angiogenesis: expression of the vascular endothelial growth factor (VEGF) protein and high microvessel density (MVD), or a large number of blood vessels associated with the tumor. Of those tumors studied, VEGF overexpression was noted in 52 percent and a high MVD was present in 32 percent. Both high MVD and VEGF were linked to significantly poorer survival (130 months versus 415 months in those with high MVD and 154 months versus 394 months in those with VEGF overexpression). Researchers noted that high MVD was also associated with recurrence and metastasis to other locations such as the abdomen, liver, lung and bone.

"Unlike most ovarian tumors which metastasize to nearby tissues or invade the lymphatic system, we suspect that the biological qualities of sex cord-stromal tumors, especially their ability to spread to and survive in distant sites of the body, explain why this type of ovarian cancer behaves so differently in patients," said Anil Sood, M.D., professor in the Departments of Gynecologic Oncology and Cancer Biology at M. D. Anderson and senior author on the study. "By honing in on how sex cord-stromal tumors utilize the blood vessels to become deadly, we can begin to test targeted anti-angiogenic therapies as possible means to control their growth."

Anti-angiogenic agents have been used in other cancers including colorectal, breast, lung and kidney cancers to slow tumor growth. Brown is currently the principal investigator on a Gynecologic Oncology Group Phase II clinical trial at M. D. Anderson to test the efficacy of bevacizumab (Avastin), a drug that blocks angiogenesis through antibodies against VEGF, in patients with sex cord-stromal tumors.

In addition to Brown and Sood, M. D. Anderson researchers contributing to this study include Alpa Nick, M.D., Ljiljana Milojevic, D.D.S. and David M. Gershenson, M.D, all from the Department of Gynecologic Oncology, and Michael Deavers, M.D., from the Department of Pathology.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Angiogenesis Linked To Poor Survival In Patients With Rare Type Of Ovarian Cancer." ScienceDaily. ScienceDaily, 12 February 2009. <www.sciencedaily.com/releases/2009/02/090205120406.htm>.
University of Texas M. D. Anderson Cancer Center. (2009, February 12). Angiogenesis Linked To Poor Survival In Patients With Rare Type Of Ovarian Cancer. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2009/02/090205120406.htm
University of Texas M. D. Anderson Cancer Center. "Angiogenesis Linked To Poor Survival In Patients With Rare Type Of Ovarian Cancer." ScienceDaily. www.sciencedaily.com/releases/2009/02/090205120406.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins